Supplementary data

Title: The anti-tumor function of the IKK inhibitor PS1145 and high levels of p65 and KLF4 are associated with the drug resistance in nasopharyngeal carcinoma cells

Hong Lok Lung^{1#*}, Rebecca Kan^{2,a#}, Wai Yin Chau¹, On Ying Man¹, Nai Ki Mak^{1,4}, Chun Hung Fong^{1,b}, Wai Ho Shuen^{2,c}, Sai Wah Tsao^{3,4}, Maria Li Lung^{2,4*}




Figure S1. (A) Apoptosis analysis of the effects of PS1145 in NPC43 cells. The TUNEL assay was used to detect the apoptotic cells on day 3 after the treatment with 32 μ M PS1145. Representative results are shown in the upper panel. The white arrows indicate the apoptotic cells. The bar chart shows the percentage of number of apoptotic cells formed after treatment with PS1145 or the solvent control (DMSO). *, p value < 0.05. (B) Western blot analysis of the protein expression of the apoptotic factor Bax after the PS1145 treatment (32 μ M).




Fig. S2

Figure S2. Cell viability in response to PS1145 (32 μ M) after treatment with *KLF4* siRNA in C666-PS1145R cells. The MTT assay was performed to detect the cell viability. Western blot analysis of the protein expression of KLF4 after siRNA knockdown in these cells. siCTL, scramble control siRNA.

C666-PS1145R




Fig. S3

Figure S3. Examination of the effects of the ROCK inhibitor (RI) Y27632 on the cell viability of C666-PS1145R in the presence or absence or various amounts of PS1145. The cell viability was detected by MTT.




Figure S4. Full immunoblots for Fig. 3. Fig. 3 is shown on the upper panel and the original blots are shown on the lower panel. The red box indicated the cropped area in the original blot.




Figure S5. Full immunoblots for Fig. 4C. Fig. 4C is shown on the left and the original blots are shown on the right. The red box indicated the cropped area in the original blot.





Figure S6. Full immunoblots for Fig. 6C. Fig. 6C is shown on the upper panel and the original blots are shown on the lower panel. Both long and short exposure versions for detection of pp65 are shown. The red box indicated the cropped area in the original blot.






Figure S7. Full immunoblots for Fig. 7B. Fig. 7B is shown on the upper panel and the original blots are shown on the lower panel. The red box indicated the cropped area in the original blot.





Figure S8. Full immunoblots for Fig. S1. Fig. S1 is shown on the upper panel and the original blots are shown on the lower panel. The red box indicated the cropped area in the original blot.






Figure S9. Full immunoblots for Fig. S2. Fig. S2 is shown on the upper panel and the original blots are shown on the lower panel. The red box indicated the cropped area in the original blot.

Table S1. Raw data of full measurements of tumor sizes in the HONE1 solevnt control group (measured in mm)

	Length	Wifth	Height		Length	Wifth	Height	Length	Wifth	H	Height	Length	Wifth	Height	Length	Wifth	Height
Animal	wk0				wk0.5			wk1				wk1.5			wk2		
1		0	0	0	10.8	6.1	1.8	0		0	0	0		0	0 0) () 0
2		0	0	0	0	0	0	8.5		5.8	1.7	16.3	8	.3 5.	1 14	13.3	6.5
3	3	0	0	0	10.8	7.8	0.5	14		8.6	3.5	11.7	13	.9 5.	5 20	9.8	6.1
4	ı	0	0	0	7.5	7.6	1.9	11.5		9.4	5	8	3	.7 2.	5 20.4	15.5	7.5
5	i	0	0	0	8.8	7.5	3.6	14.6		6.3	1.9	10.5	5	.2 6.	4 17.2	2 13.7	7 7
6	6	0	0	0	10.1	9.2	2.9	4.6		7.6	3	14.3	10	.9 2.	7 13.5	5 10.6	5.2
7	7	0	0	0	0	0	0	16.8		8.9	2.8	14.7	7	.4 4.	4 21	1 12	2 5.2
8	3	0	0	0	11.3	5.7	1.4	13.6		9.7	3.6	18.4	1	10 7.	9 18	9.8	3 4.6
9		0	0	0	16.1	8	1.9	11		9.3	2.9	8.3	6	.5 5.	4 20.4	1 12.4	6.5
10		0	0	0	9.7	6.9	0.5	11.1		9.3	2.3	18	9	.1 4.	6 21.8	3 14.3	3 6
11		0	0	0	0	0	0	10.7		9	5.5	20.7	10	.7 4.	6 22.1	12.1	1 4.5
12		12	5	0.5	14.1	6.5	1.5	15.4		7.5	2.3	17.6	14	.2 5.	7 14.7	7 12	2 5.5

Table S2. Averge tumor sizes in the HONE1 solevnt control group (measured in mm³)

			HONE1 sol	vent control	- tumor size	mm3	
_		week	0	0.5	1	1.5	2
Γ		1	0	118.584	0	0	0
1		2	0	0	83.81	689.979	1210.3
1		3	0	42.12	421.4	894.465	1195.6
1		4	0	108.3	540.5	74	2371.5
1	_	5	0	237.6	174.762	349.44	1649.48
1	animal	6	0	269.468	104.88	420.849	744.12
1	an.	7	0	0	418.656	478.632	1310.4
1		8	0	90.174	474.912	1453.6	811.44
1		9	0	244.72	296.67	291.33	1644.24
1		10	0	33.465	237.429	753.48	1870.44
1		11	0	0	529.65	1018.854	1203.345
L		12	30	137.475	265.65	1424.544	970.2
		average	2.727273	105.7565	322.5745	713.5612	1361.915
		SD	4.52267	51.86023	82.15622	225.9429	242.7365

Table S3. Raw data of body weights in the HONE1 solevnt control group (measured in g)

		HONE1 solvent	control			
	wk	0	0.5	1	1.5	2
	1	14.9	16.3	14	15	16
	2	16.6	15.7	15.7	17.8	19.6
	3	13.9	14.6	13.9	17.9	18.2
	4	14.8	15.4	15.2	16.5	18.2
l _	5	16.3	14.9	17.3	17.2	17.5
μ	6	15.2	16.5	15	16	17.8
animal	7	15.6	13.8	14.9	18.6	16.7
	8	14.2	17.1	16.2	15.5	18.7
	9	13.7	15.5	15.2	16.6	17.2
	10	15.6	13.7	16.1	16	18.3
	11	16.4	15.6	16.8	15.8	16.2
	12	15.3	14.3	17.2	17.4	17.4
	average	15.20833333	15.28333	15.625	16.69167	17.65
	SD	0.479800306	0.53165	0.566539	0.547082	0.52158

Table S4. Raw data of full measurements of tumor sizes in the HONE1 PS1145 treatment group (measured in mm)

	Length	Wifth		Height	Length	Wifth	Height									
Animal	wk0				wk0.5			wk1			wk1.5			wk2		
1		0	0	0	10.5	5.4	1.8	14.2	10.3	0.5	14.5	11.5	4	16.8	12.8	4.3
2	2	8	5	0.5	10.9	6.5	3	12	8.8	0.5	11.2	11.4	3.1	14	9.8	4.8
3	3	0	0	0	14.2	7.8	0.5	11.2	6.5	0.5	13.7	12.9	3	14.8	12.1	2.1
4	ı	0	0	0	0	0	0	16.8	7.8	2.7	9.7	7.8	3	17.3	12	5.3
5	5	0	0	0	11.4	6.9	1.8	16.4	7.9	4	19.2	8.2	3	14.7	13.4	4.5
6	6	0	0	0	3.6	4.1	0.5	16.6	10.3	3	14.2	9	2.7	14.9	10.7	6.7
7	7	0	0	0	0	0	0	10.4	9.8	0.5	1.8	8.7	3.3	16.6	12.2	6.3
8	3	0	0	0	11.2	7.3	1.9	11.7	7.9	3.3	14.3	9.3	2.4	18.6	15.4	2.6
9)	0	0	0	13	7	0.5	15.6	8.6	2.5	14	14.7	1.8	17.8	16	2.1
10)	0	0	0	0	0	0	10.1	8.6	0.5	14.7	12	3	13.9	11.8	2.5
11		0	0	0	0	0	0	12.2	7.5	0.5	12.3	7.9	5.1	19.7	8.7	2.6
12	2	0	0	0	0	0	0	10.6	6.9	2.5	17.4	10	3.1	18.2	13.4	4.8

Table S5. Averge tumor sizes in the HONE1 PS1145 treatment group (measured in mm³)

			HONE1 + PS1145 - tumor size mm3								
		week	0	0.5	1	1.5	2				
ſ		1	0	102.06	73.13	667	924.672				
ı		2	20	212.55	52.8	395.808	658.56				
ı		3	0	55.38	36.4	530.19	376.068				
ı		4	0	0	353.808	226.98	1100.28				
ı	_	5	0	141.588	518.24	472.32	886.41				
ı	animal	6	0	7.38	512.94	345.06	1068.181				
ı	ani.	7	0	0	50.96	51.678	1275.876				
ı		8	0	155.344	305.019	319.176	744.744				
ı		9	0	45.5	335.4	370.44	598.08				
ı		10	0	0	43.43	529.2	410.05				
ı		11	0	0	45.75	495.567	445.614				
L		12	0	0	182.85	539.4	1170.624				
		average	1.666667	59.9835	209.2273	411.9016	804.9299				
		SD	2.886751	37.47365	93.72937	82.39778	155.9302				

Table S6. Raw data of body weights in the HONE1 PS1145 treatment group (measured in g)

		HONE1 + PS114	45			
	wk	0	0.5	1	1.5	2
	1	16.2	16.5	15.6	17.7	18.6
	2	15.7	16.4	16.4	18.1	19.2
	3	15.9	16.5	16.8	17.6	18.1
	4	17.4	15.9	16.9	17	18.7
_	5	16.3	16	18	18.2	17.4
па	6	15.3	15.7	17.2	17.3	17.6
animal	7	16.6	15	16.9	17.7	18.4
(0	8	16.3	18.1	16	16.5	17.4
	9	15.1	16.3	17.3	17.5	16.9
	10	17.7	15	18.6	16.8	19.2
	11	14.8	18.2	15.4	17.1	18.8
	12	16.1	16.4	16.6	18.5	17.4
	average	16.11666667	16.33333	16.80833	17.5	18.14167
	SD	0.429499356	0.498331	0.460957	0.296954	0.391651

Table. S7. Raw data of full measurements of tumor sizes in the C666 solevnt control group (measured in mm)

	Length	Wifth		Height	Length	Wifth	Height									
Animal	wk0				wk0.5			wk1			wk1.5			wk2		
1		8	6	0.5	8	4	0.5	11.4	5.5	5 1.1	11.6	6.1	3.1	13.8	8.2	4.2
2	2	16	4	0.5	5	3	0.5	9.6	5.6	3 2.6	9.5	8.4	2.6	12.7	10.3	4.7
3	3	0	0	0	15	3	0.5	11.9	(3 2.3	9.9	8.1	4.1	14.7	9.4	4.1
4	Į.	0	0	0	4	4	5	11.9	6.6	3 1.8	13	7.9	2.5	14.7	8	4.4
5	5	9	6	0.5	0	0	0	8.2	5.2	2 1.1	9	7	2.7	14.5	8.4	3.4
6	6	0	0	0	14	3	0.5	10.1	5.3	3 1.5	13	7.3	2.3	15.3	7.7	2
7	7	7	6	1	9	4	0.5	12.5	4.6	0.5	13.4	6.9	1.8	6.6	8.6	2.3
8	3	0	0	0	14	3	0.5	7.4	4.6	0.5	9	6.3	2.1	13.4	9.1	4.1
9)	0	0	0	8	5	0.5	12.2	4.	2.2	12.4	6	2.4	13	9.5	5
10)	8	4	5	13	4	0.5	5.5		0.5	12.7	5.7	0.5	11.1	8.7	4.3
11		7	5	0.5	0	0	0	13.2	5.5	1.7	10.6	7.7	4	11.1	7	3.5

Table S8. Averge tumor sizes in the C666 solevnt control group (measured in mm³)

C666 solvent control - tumor size mm3 1.5 week 219.356 475.272 24 16 68.97 2 32 7.5 139.776 207.48 614.807 3 0 22.5 164.22 328.779 566.538 0 80 141.372 256.75 517.44 animal 27 0 46.904 170.1 414.12 6 0 21 80.295 218.27 235.62 7 42 18 28.75 166.428 130.548 8 0 21 17.02 499.954 119.07 9 0 20 126.148 178.56 617.5 10 26 160 13.75 36.195 415.251 11 17.5 0 123.42 326.48 271.95 average 27.85 21.6 88.1655 200.8112 428.3728 24.53287 11.27793 28.79931 44.73609 83.89311 SD

Table S9. Raw data of body weights in the C666 solevnt control group (measured in g)

			C666 solvent co	ntrol			
		wk	0	0.5	1	1.5	2
Γ		1	18.2	18.9	19.1	18.9	19.6
ı		2	20	18.4	19.8	18.9	18.5
ı		3	16.5	17.8	18.5	19.8	18.9
ı		4	19.4	16.7	18.2	17.9	19.5
ı	<u>a</u>	5	18.3	18.6	17.3	17.7	19.1
ı	animal	6	20.8	16.8	18.6	18	18.1
ı	a	7	18.8	20.5	17	18.1	19.3
ı		8	19.2	18.5	18.8	18.6	19
ı		9	17.1	18.4	19.1	18.9	19.6
ı		10	19.2	19.2	18.2	17	19.7
ı		11	19.8	17.9	18.8	18.4	18.2
		average	18.84545455	18.33636	18.49091	18.38182	19.04545
		SD	0.630223626	0.533044	0.402153	0.377371	0.284924

Table S10. Raw data of full measurements of tumor sizes in the C666 PS1145 treatment group (measured in mm)

	Length	n Wifth	Н	leight	Length	Wifth	Height									
Animal	wk0				wk0.5			wk1			wk1.5			wk2		
	1	0	0	0	4	4	0.5	7.9	6	1.5	11.3	6.	1 1.4	11.8	5.6	1.3
	2	0	0	0	5	4	0.5	5.6	5.6	0.9	10.8		7 0.5	13	6.8	3 1.5
	3	0	0	0	12	3	0.5	5	4.4	1.1	11.3	7.	1 1.6	15.4	9.2	2 1.6
	4	5	5	0.5	3	3	0.5	11.4	5.5	1.3	9.2		4 0.5	7.1	7.8	3 2.2
	5	0	0	0	0	(0	10.3	5.9	1.2	0		0 0	12.1	7.4	4
	6	7	5	0.5	10	4	0.5	5	4.5	0.5	8.4	0.3	2 1.5	8.9	8.3	3 2.4
	7	8	4	0.5	5	4	0.5	8.8	6.1	0.5	10.5	6.	7 3.2	10.5	6.6	3 2.4
	8	10	6	1	0	(0	10.8	6.3	0.5	4.7	3.4	4 0.5	9.5	7	7 2
	9	7	7	0.5	13	3	0.5	7.7	6.4	1.4	6		3 1.7	7.2	5.9) 2
1	0	11	5	0.5	6	4	0.5	11	5	1.3	9.5	6.	5 2.2	8.2	8.8	3 1.8
1	1	0	0	0	0	(0	9.8	4.4	0.5	6.3	4.	5 0.5	9.6	5.1	0.5
1	2	0	0	0	6	5	0.5	7.7	5.8	1.4	10.2	6.3	3 2.1	12.1	8.4	3

Table S11. Averge tumor sizes in the C666 PS1145 treatment group (measured in mm³)

		C666 + PS	1145 - tumo	r size mm3		
	week	0	0.5	1	1.5	2
	1	0	8	71.1	96.502	85.904
	2	0	10	28.224	37.8	132.6
	3	0	18	24.2	128.368	226.688
	4	12.5	4.5	81.51	18.4	121.836
_	5	0	0	72.924	0	358.16
Ша	6	17.5	20	11.25	2.52	177.288
animal	7	16	10	26.84	225.12	166.32
	8	60	0	34.02	7.99	133
	9	24.5	19.5	68.992	61.2	84.96
	10	27.5	12	71.5	135.85	129.888
	11	0	0	21.56	14.175	24.48
	12	0	15	62.524	134.946	304.92
	average	13.16667	9.75	47.887	71.90592	162.1703
	SD	9.038638	3.743934	12.73131	35.95264	47.27306

Table S12. Raw data of body weights in the C666 PS1145 treatment group (measured in g)

		C666 + PS1145				
	wk	0	0.5	1	1.5	2
	1	18.3	18.8	17.6	18.5	17.6
	2	19.1	18	19	18.4	19.6
	3	18.7	19.7	17.7	17.6	18.9
	4	18.6	17.2	18.2	16.8	18.7
l _	5	16	18.3	18.8	18.1	19.1
animal	6	18.4	18.5	17.8	17.9	17.9
<u> </u>	7	17.4	18.4	18.8	18.4	19.3
	8	18.1	18.3	18.1	17.3	19
	9	17.8	17.5	18.2	18.1	18.8
	10	18	19.5	19.5	18	18.1
	11	18.4	16.5	17.7	18	18.1
	12	19.2	17.4	18.2	17.8	18.4
	average	18.16666667	18.175	18.3	17.90833	18.625
	SD	0.42604595	0.464721	0.3	0.244446	0.303858